Pending — not yet graded
“Favors the pharmaceuticals sector, seeing significant long-term opportunities in exports, particularly in GLP-1 drugs and contract development and manufacturing (CDMO). He expects the entire value chain to benefit from patent expiries globally.”
Pharmaceuticals SectorBullishCalled 06 Jul 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.
Read the original articleSee Sridhar Sivaram’s full track record